

 **先声药业** **Sincere** Join us,
if you are stronger!

Simcere Career Development and Recruitment Forum



Event Language:

Chinese

Time:

7–10pm,
Thursday, 09/14/2017

Venue:

Li Ka Shing Learning and
Knowledge Center, Room LK120,
291 Campus Drive, Palo Alto,
CA 94305

Opening Remark



Jinsheng
Ren

Founder and Chairman

- Guest professor, China Pharmaceutical University, Nanjing Medical University, Nanjing University of Chinese Medicine
- Vice President, PhIRDA
- Vice Chairman of Jiangsu Provincial Science and Technology Association
- The second prize of China National Science & Technology Progress Award

Keynote Speaker



Hua Mu
M.D., Ph.D.

Chief Scientific Officer

- Ph.D. from UC Berkeley
- >20 NCEs or biologics (Avastin, Xeloda, Abraxane, & Fruquintinib)
- Senior leadership positions at WuXi, Hutchison, Genentech, Biogen, Abraxis & Roche
- Led 5 co-development partnerships between MNCs and local partners in China

Panel Speakers



Honggang
Feng

President
Simcere Pharmaceutical Group

- 22 years of industrial experiences with R&D, sales, marketing, etc. and a trained physician
- An industry-wide reputation in growing the sales of a product by 7 times to 2 bn RMB when served as GM at Shihuida Pharma



Yongzhong Wang
Ph.D.

President
Pharmaceuticals

- Ph.D. from Tufts University
- CEO Chengdu KangHong Biotechnology
- Senior leadership in state of art cGMP manufacturing
- Led worldwide R&D of Conbercept, and filed Ph3 IND with FDA, directly bypass Ph1&2
- Led CMC for Conbercept
- Staff Scientist/Project Leader, Genzyme



Alan Yuan

VP, International BD

- MBA from University of Chicago, Engineering bachelor's degree from Tongji University
- Board member of Asian Investment Bank BU of Bank of America Merrill Lynch, global market financing and M&A
- Credit Suisse
- Deutsche Bank



Xinyan Cindy Zhao
Ph.D.

VP, SBP

- Ph.D. from Fudan University
- >20 biologics (3 in Ph1&2, 1 NDA with FDA)
- Senior leadership positions in Eisai-Morphotek and Merck Serono
- 7 years' academic experience in Univ. of Rochester, Yale Univ., Univ. of Pennsylvania



Sue Xu
Ph.D.

Executive Director
Translational Medicine, SBP

- PhD from Boston College, USA
- 20+ years of industrial experience in biological drug development at Pfizer, EMD Serono, J&J
- Major contributor of discovery and develop of EMD Serono's recently approved anti-PD-L1, and multiple IND preparation and patent filing



Xujie Duan
Ph.D.

Director,
Head of Protein Production

- Ph.D. from East China Science and Technology University
- >7 years' leadership in biologics development in Simcere
- Major contributor of 2 INDs with CFDA



Bin Zhu
PhD, MD

Senior Director
Head of Discovery Biology & Pharmacology

- PhD from University of Cambridge and MD from Xiangya Medical School
- 18 years' experience in discovery & development at Eisai Europe, Sanofi, Takeda & GSK Singapore
- Led 8 molecules to pre-clinical, 1 to clinical & 2 to market



Simcere Pharmaceutical Group

Simcere is a leading pharmaceutical company specializing in development, manufacturing, and marketing of branded generic and innovative medicines in China, focusing on Oncology, Neurology, anti-infection, inflammation and cardiovascular diseases. Simcere has introduced three first-to-market products worldwide and six ones domestically.

Founded in 1995, Simcere currently has 4,000+ employees in China, with one R&D center, two sale and marketing subsidiaries and four manufacturing facilities. We have also set up three offices in United States in order to seek for and provide more advanced and effective therapeutics for patients. In 2015, the State Key Lab of Translational Medicine and Innovative Drug Development were approved and established, which signaled our strong R&D pipeline.

Simcere have has 50+ products on China market and drives a strong topline growth of over 30% for the past three years. We have a strong development team and a commercial platform; both led by highly experienced industry veterans.

Simcere actively pursues partnering opportunities for both R&D stage and launched products. Our partners include BMS, Daiichi Sankyo, GSK, and Amgen, etc. Simcere has also participated in 8 prestigious venture capitals and invested over \$1.5 billion into global innovation. Three companies we invested are on the list of 2016 top 50 smartest companies in the world by MIT Technology Review.

As part of the efforts to explore an open innovation model, in 2014, Precision Med BioSciKin was officially founded. It is an open platform for information and resources' share and integration via R&D, manufacturing and sales and marketing.

Simcere has been on the list of Top 100 Chinese Pharmaceutical Companies for six consecutive years. It is also selected as the most innovative pharmaceutical companies in China as well as the best employer.